We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors focused on the Medical space have likely heard of Zoetis (ZTS - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Zoetis is a member of our Medical group, which includes 866 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ZTS is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ZTS's full-year earnings has moved 2.66% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ZTS has moved about 43.87% on a year-to-date basis. In comparison, Medical companies have returned an average of 0.83%. This means that Zoetis is outperforming the sector as a whole this year.
To break things down more, ZTS belongs to the Medical - Drugs industry, a group that includes 172 individual companies and currently sits at #92 in the Zacks Industry Rank. On average, stocks in this group have gained 5.38% this year, meaning that ZTS is performing better in terms of year-to-date returns.
ZTS will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?
Investors focused on the Medical space have likely heard of Zoetis (ZTS - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Zoetis is a member of our Medical group, which includes 866 different companies and currently sits at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. ZTS is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ZTS's full-year earnings has moved 2.66% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ZTS has moved about 43.87% on a year-to-date basis. In comparison, Medical companies have returned an average of 0.83%. This means that Zoetis is outperforming the sector as a whole this year.
To break things down more, ZTS belongs to the Medical - Drugs industry, a group that includes 172 individual companies and currently sits at #92 in the Zacks Industry Rank. On average, stocks in this group have gained 5.38% this year, meaning that ZTS is performing better in terms of year-to-date returns.
ZTS will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.